Testicular carcinoma is a rare tumour but the most frequently occurring form of cancer in men aged 18-35 years. In metastatic disease, following orchidectomy three or four courses of combination chemotherapy with cisplatin are given. With a general chance of cure of 80-90%, testicular cancer is still regarded as a model for a form of cancer that is curable. Due to this favourable prognosis--and to its rising incidence--the group of people who survive testicular cancer is growing and more attention is being paid to the risk of adverse consequences of treatment: secondary tumours and cardiovascular morbidity. Shared care follow-up for testicular cancer survivors with participation of both primary and secondary care is currently developed.
Written by:
Nuver J, Oosting SF, Gietema JA. Are you the author?
Universitair Medisch Centrum Groningen, afd. Medische Oncologie, Groningen, The Netherlands.
Reference: Ned Tijdschr Geneeskd. 2011;155(45):A4092.
PubMed Abstract
PMID: 22085577
Article in Dutch.
UroToday.com Testicular Cancer Section
